Kiadis receives $3.9M boost for blood cancer trial

06/27/2013 | Genetic Engineering & Biotechnology News

A division of the Netherlands' Ministry of Economic Affairs granted Kiadis Pharma a loan worth around $3.9 million to support midstage trials of ATIR. The drug candidate is designed to permit stem cell transplantations for blood cancer patients with partially mismatched or haploidentical donors.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA